Tarsus Pharmaceuticals Reports Strong Q1 2026 Results, Driven by XDEMVY Sales & China Milestone
TARS sits 65% above its 52-week low of $38.51.
Summary
Tarsus Pharmaceuticals reported strong Q1 2026 financial results with significant revenue growth from XDEMVY, a reduced net loss, and a $15.0 million milestone from China regulatory approval, alongside pipeline advancements.
Key Events · Earnings and Guidance · TARS
-
Strong Q1 2026 Revenue Growth
Net product sales for XDEMVY increased over 85% year-over-year to $145.4 million, contributing to total revenues of $162.1 million.
-
Significantly Reduced Net Loss
The company's net loss decreased substantially to $7.0 million in Q1 2026, compared to $25.1 million in Q1 2025.
-
China Regulatory Approval & Milestone Payment
GrandPharma obtained regulatory approval for TP-03 in China, triggering a $15.0 million milestone payment to Tarsus Pharmaceuticals.
-
Pipeline Advancement with Two Phase 2 Initiations
Tarsus initiated Phase 2 clinical trials for TP-04 (ocular rosacea) and TP-05 (Lyme disease prophylaxis), with topline results anticipated in H1 2027.
Analysis · TARS · Life Sciences
Tarsus Pharmaceuticals reported robust financial performance for Q1 2026, building on the strong results announced in the concurrently filed 8-K. The company achieved a significant 85% year-over-year increase in net product sales for XDEMVY, reaching $145.4 million, and substantially reduced its net loss from $25.1 million in Q1 2025 to $7.0 million. A key highlight is the $15.0 million milestone payment received from GrandPharma following regulatory approval of TP-03 in China, marking a new revenue stream from international collaboration. Furthermore, the company advanced its pipeline by initiating two Phase 2 clinical trials for TP-04 (ocular rosacea) and TP-05 (Lyme disease prophylaxis), with topline results expected in the first half of 2027. The company maintains a healthy liquidity position with $388.7 million in cash, cash equivalents, and marketable securities, which management believes is sufficient for at least the next 12 months. Director Katherine Goodrich adopted a routine 10b5-1 trading plan for a modest number of shares, which is a pre-planned, non-discretionary sale.
At the time of this filing, TARS was trading at $63.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $38.51 to $85.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.